Editorial: Belatacept: The promises and challenges of belatacept and costimulatory blockade

American Journal of Transplantation

Volumn 10, Issue 3, 2010, Pages 441-442

  Kaplan, B ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; ABATACEPT; ANTIBODY CONJUGATE; CALCINEURIN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; ENTERITIS; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; DRUG ANTAGONISM; KIDNEY DISEASE; METHODOLOGY; NOTE; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

CALCINEURIN; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOSPORINE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; TREATMENT OUTCOME;

EID: 76949094403     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03026.x     Document Type: Editorial

References (6)

1. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005 353 : 770 781.
2. Vincenti F, Charpentier B, Vanrenterghem Y et al. A phase III study of belatacept-based immunosuppression regimens vs. cyclosporine I renal transplant recipients (benefit study). Am J Transplant 2010 10 : 559 570.
3. Durrbach A, Pestana JM, Pearson T et al. A phase III study of belatacept vs cyclosporine in kidney transplants from extended criteria donors (benefit-ext study). Am J Transplant 2010 10 : 571 581.
4. Famulski K, Einecke G, Sis B et al. Canonical T cell mediated rejection in human kidney transplants has a favorable prognosis even when rejection is late or has arthritis. Am J Transplant 2010, in press.
5. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of Improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004 4 : 378 383.
6. Carson KR, Focosi D, Major EO et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: A review from the research on adverse drug events and report (RADAR) project. Lancet Oncol 2009 10 : 816 824.